Page last updated: 2024-09-05

sb 203580 and lentinan

sb 203580 has been researched along with lentinan in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(lentinan)
Trials
(lentinan)
Recent Studies (post-2010) (lentinan)
3,48941,13749536152

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dai, S; Dong, L; Li, H; Liu, Q; Peng, Y; Yuan, J1

Other Studies

1 other study(ies) available for sb 203580 and lentinan

ArticleYear
Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: Animals; Anthracenes; Bone Marrow; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; I-kappa B Proteins; Imidazoles; Lentinan; Leukocytes; Macrophages; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neutrophils; NF-kappa B; Pyridines

2016